{
    "hands_on_practices": [
        {
            "introduction": "Effective neurogenetic counseling often begins with a solid understanding of population genetics. In an increasingly diverse world, many individuals have mixed ancestry, which can significantly influence their risk for certain genetic conditions. This practice will ground you in the Hardy–Weinberg equilibrium, demonstrating how to estimate carrier frequencies for a recessive disorder within admixed populations . Mastering this calculation is a foundational skill for providing accurate, ancestry-informed risk assessments to patients and families.",
            "id": "4504035",
            "problem": "A recessive neurometabolic condition is caused by a single autosomal pathogenic allele at a locus with two alleles: the normal allele with frequency $p$ and the pathogenic allele with frequency $q$, where $p + q = 1$. In neurogenetic counseling, ancestry-specific pathogenic allele frequencies are often available, and counseling requires projecting expected carrier rates under Hardy–Weinberg equilibrium. Consider two distinct, panmictic populations in which mating occurs at random across ancestries within each population. Each population is an admixture of two ancestral groups, $\\mathcal{A}$ and $\\mathcal{B}$, with ancestry-specific pathogenic allele frequencies $q_{\\mathcal{A}} = 0.014$ and $q_{\\mathcal{B}} = 0.0025$. The ancestry proportions are:\n- For Population $1$: $w_{\\mathcal{A},1} = 0.65$ and $w_{\\mathcal{B},1} = 0.35$.\n- For Population $2$: $w_{\\mathcal{A},2} = 0.25$ and $w_{\\mathcal{B},2} = 0.75$.\n\nAssume the gene is autosomal, the condition is strictly recessive, and within each population the Hardy–Weinberg equilibrium holds in the sense that random mating, no selection, negligible mutation over one generation, and no migration into or out of the population apply. Using fundamental principles of Mendelian inheritance and Hardy–Weinberg equilibrium, derive from first principles the expected heterozygote carrier rate in each population based on the provided ancestry-specific pathogenic allele frequencies and the ancestry mixture proportions.\n\nExpress each carrier rate as a decimal (for example, $0.0123$), round your answer to four significant figures, and report the two carrier rates in order as $(\\text{Population }1, \\text{Population }2)$. The final answer must be given as a row matrix with two entries.",
            "solution": "The problem is valid as it is scientifically grounded in established principles of population genetics, specifically the Hardy–Weinberg equilibrium and admixture models, is well-posed with all necessary data for a unique solution, and is expressed in objective, formal language. We proceed with the solution.\n\nThe problem requires the calculation of heterozygote carrier rates in two distinct admixed populations. The fundamental principle for an admixed population is that the frequency of an allele is the weighted average of its frequencies in the ancestral source populations, where the weights are the proportions of ancestry.\n\nLet $q$ represent the frequency of the pathogenic allele and $p$ represent the frequency of the normal allele. For a biallelic locus, the allele frequencies sum to unity: $p + q = 1$. Under Hardy–Weinberg equilibrium (HWE), the genotype frequencies for a given population are $p^2$ for normal homozygotes, $2pq$ for heterozygote carriers, and $q^2$ for affected homozygotes, where $p^2 + 2pq + q^2 = 1$. The heterozygote carrier rate corresponds to the genotype frequency $2pq$.\n\nThe problem provides the pathogenic allele frequencies for two ancestral groups, $\\mathcal{A}$ and $\\mathcal{B}$:\n-   $q_{\\mathcal{A}} = 0.014$\n-   $q_{\\mathcal{B}} = 0.0025$\n\nWe will calculate the carrier rate for each of the two admixed populations.\n\n**Population 1**\n\nThe ancestry proportions for Population $1$ are given as $w_{\\mathcal{A},1} = 0.65$ and $w_{\\mathcal{B},1} = 0.35$. The overall frequency of the pathogenic allele in Population $1$, which we denote as $q_1$, is the weighted average of the ancestral frequencies:\n$$q_1 = w_{\\mathcal{A},1} q_{\\mathcal{A}} + w_{\\mathcal{B},1} q_{\\mathcal{B}}$$\nSubstituting the given numerical values:\n$$q_1 = (0.65)(0.014) + (0.35)(0.0025)$$\n$$q_1 = 0.0091 + 0.000875$$\n$$q_1 = 0.009975$$\nThe frequency of the corresponding normal allele, $p_1$, is:\n$$p_1 = 1 - q_1 = 1 - 0.009975 = 0.990025$$\nThe expected heterozygote carrier rate for Population $1$, denoted $C_1$, is calculated using the HWE formula:\n$$C_1 = 2 p_1 q_1$$\n$$C_1 = 2 (0.990025)(0.009975)$$\n$$C_1 = 0.01975199875$$\nThe problem requires the answer to be rounded to four significant figures. Thus, the carrier rate for Population $1$ is $C_1 \\approx 0.01975$.\n\n**Population 2**\n\nThe ancestry proportions for Population $2$ are given as $w_{\\mathcal{A},2} = 0.25$ and $w_{\\mathcal{B},2} = 0.75$. We follow the same procedure to find the pathogenic allele frequency in Population $2$, denoted $q_2$:\n$$q_2 = w_{\\mathcal{A},2} q_{\\mathcal{A}} + w_{\\mathcal{B},2} q_{\\mathcal{B}}$$\nSubstituting the given numerical values:\n$$q_2 = (0.25)(0.014) + (0.75)(0.0025)$$\n$$q_2 = 0.0035 + 0.001875$$\n$$q_2 = 0.005375$$\nThe frequency of the corresponding normal allele, $p_2$, is:\n$$p_2 = 1 - q_2 = 1 - 0.005375 = 0.994625$$\nThe expected heterozygote carrier rate for Population $2$, denoted $C_2$, is:\n$$C_2 = 2 p_2 q_2$$\n$$C_2 = 2 (0.994625)(0.005375)$$\n$$C_2 = 0.01069265625$$\nRounding to four significant figures, the carrier rate for Population $2$ is $C_2 \\approx 0.01069$.\n\nThe final answer requires the two carrier rates for Population $1$ and Population $2$, in that order, expressed as a row matrix.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.01975 & 0.01069\n\\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "Moving from population-level risk to individual diagnostic testing requires a different set of quantitative skills. A positive test result is not an absolute certainty; its true meaning depends on the test's intrinsic characteristics and the prevalence of the condition. This exercise guides you through the application of Bayes' theorem to determine the Positive Predictive Value ($PPV$) of a genetic test . By calculating the $PPV$, you will learn how to translate a raw test result into a meaningful posterior probability, a critical step in communicating diagnostic information with clarity and confidence.",
            "id": "4503951",
            "problem": "A neurogenetics clinic is counseling a patient from a family with multiple cases of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). The clinic uses a repeat-primed Polymerase Chain Reaction (PCR) assay, with reflex Southern blot, to detect pathogenic hexanucleotide expansions in the C9orf72 gene. In a rigorously phenotyped subgroup—patients with clinically definite ALS and at least one first-degree relative with ALS or FTD—the true prevalence of a pathogenic C9orf72 expansion is $\\pi = 0.15$. Independent validation studies for this assay report sensitivity $Se = 0.98$ and specificity $Sp = 0.997$ for detecting truly pathogenic expansions.\n\nStarting from the fundamental definitions of sensitivity (the probability of a positive test given that a pathogenic expansion is present), specificity (the probability of a negative test given that a pathogenic expansion is absent), and prevalence (the prior probability that a pathogenic expansion is present in this subgroup), and using Bayesian inference with the law of total probability, derive an expression for the Positive Predictive Value (PPV), defined as the posterior probability that a pathogenic expansion is present conditional on a positive test. Then, compute the numerical value of $PPV$ for the given $Se$, $Sp$, and $\\pi$.\n\nRound your final numerical $PPV$ to four significant figures. Express your answer as a decimal and do not include a percentage sign. Finally, explain briefly how this $PPV$ would be used in neurogenetic counseling for a patient with a positive test in this subgroup.",
            "solution": "The problem as stated is scientifically grounded, well-posed, and contains all necessary information for a complete and unique solution. The scenario is a standard application of Bayesian inference in the context of medical diagnostics, a core concept in biostatistics and epidemiology. All provided values are realistic for the clinical context described. The problem is therefore deemed valid.\n\nThe task is to derive an expression for the Positive Predictive Value ($PPV$), compute its numerical value, and explain its clinical utility.\n\nLet us define the following events:\n- $D$: The event that a patient from the specified subgroup has a pathogenic $C9orf72$ expansion.\n- $D^c$: The event that a patient from the specified subgroup does not have a pathogenic $C9orf72$ expansion.\n- $T^+$: The event that the diagnostic test returns a positive result.\n- $T^-$: The event that the diagnostic test returns a negative result.\n\nFrom the problem statement, we are given the following probabilities:\n- The prevalence, or prior probability of having the pathogenic expansion, is $P(D) = \\pi = 0.15$.\n- The probability of not having the expansion is therefore $P(D^c) = 1 - P(D) = 1 - \\pi = 1 - 0.15 = 0.85$.\n- The sensitivity of the assay is the probability of a positive test given the presence of the expansion: $Se = P(T^+ | D) = 0.98$.\n- The specificity of the assay is the probability of a negative test given the absence of the expansion: $Sp = P(T^- | D^c) = 0.997$.\n\nThe Positive Predictive Value ($PPV$) is defined as the posterior probability that the expansion is present, conditional on a positive test result. In probabilistic notation, this is $P(D | T^+)$.\n\nWe use Bayes' theorem to express the $PPV$:\n$$PPV = P(D | T^+) = \\frac{P(T^+ | D) P(D)}{P(T^+)}$$\nThe term in the denominator, $P(T^+)$, is the total probability of obtaining a positive test result. It can be expanded using the law of total probability, considering the two mutually exclusive scenarios: the patient has the expansion ($D$) or does not have the expansion ($D^c$).\n$$P(T^+) = P(T^+|D)P(D) + P(T^+|D^c)P(D^c)$$\nThe terms in this expansion are:\n- $P(T^+|D)$ is the sensitivity, $Se$.\n- $P(D)$ is the prevalence, $\\pi$.\n- $P(D^c)$ is $1 - \\pi$.\n- $P(T^+|D^c)$ is the probability of a positive test given that the expansion is absent. This is the false positive rate, which is equal to $1$ minus the specificity ($Sp$).\n$$P(T^+|D^c) = 1 - P(T^-|D^c) = 1 - Sp$$\nSubstituting these terms into the expression for $P(T^+)$:\n$$P(T^+) = (Se)(\\pi) + (1 - Sp)(1 - \\pi)$$\nNow, we substitute this full expression for $P(T^+)$ back into the Bayes' theorem formula for $PPV$. This gives the final derived expression for $PPV$ in terms of sensitivity, specificity, and prevalence:\n$$PPV = \\frac{Se \\cdot \\pi}{Se \\cdot \\pi + (1 - Sp)(1 - \\pi)}$$\nThis completes the first part of the task.\n\nNext, we compute the numerical value of the $PPV$ using the provided data:\n- $Se = 0.98$\n- $Sp = 0.997$\n- $\\pi = 0.15$\n\nWe substitute these values into the derived formula:\n$$PPV = \\frac{(0.98) \\cdot (0.15)}{(0.98) \\cdot (0.15) + (1 - 0.997)(1 - 0.15)}$$\nFirst, we calculate the numerator, which represents the probability of a true positive result in the population:\n$$\\text{Numerator} = 0.98 \\times 0.15 = 0.147$$\nNext, we calculate the terms in the denominator. The first term is the same as the numerator. The second term represents the probability of a false positive result in the population:\n$$\\text{False Positive Term} = (1 - 0.997) \\times (1 - 0.15) = (0.003) \\times (0.85) = 0.00255$$\nThe denominator is the sum of the true positive and false positive probabilities:\n$$\\text{Denominator} = 0.147 + 0.00255 = 0.14955$$\nFinally, we compute the $PPV$:\n$$PPV = \\frac{0.147}{0.14955} \\approx 0.9829488465$$\nThe problem requires rounding the final numerical value to four significant figures. The fifth significant figure is a $4$, so we round down.\n$$PPV \\approx 0.9829$$\n\nLastly, we explain the use of this $PPV$ in neurogenetic counseling.\nA $PPV$ of $0.9829$ signifies that for a patient within this specific high-risk subgroup (clinically definite ALS with a positive family history) who receives a positive test result, there is a $98.29\\%$ probability that they genuinely possess the pathogenic $C9orf72$ expansion. In a counseling session, this extremely high value allows the genetic counselor to communicate with a very high degree of confidence that the positive test result is a true positive. It effectively confirms that the genetic basis for the patient's neurological disease is the $C9orf72$ expansion. This information is critical for several reasons:\n1.  It provides a definitive molecular diagnosis, often concluding a lengthy and uncertain \"diagnostic odyssey\" for the patient and family.\n2.  It informs prognosis, although the clinical course of $C9orf72$-related disease can be variable.\n3.  It solidifies the basis for discussing potential participation in gene-specific clinical trials or future therapies.\n4.  Crucially, it quantifies the risk for other family members. Since the pathogenic expansion is inherited in an autosomal dominant pattern, it means a patient's children and full siblings each have a $50\\%$ a priori risk of inheriting the expansion. The confirmation of the expansion in the patient enables predictive genetic counseling and testing for at-risk relatives, should they choose to learn their own status.",
            "answer": "$$\n\\boxed{0.9829}\n$$"
        },
        {
            "introduction": "Neurogenetics often pushes the boundaries of diagnostic technology, particularly when dealing with conditions that are not inherited in a straightforward manner. Somatic mosaicism, where a mutation is present in only a subset of the body's cells, is a key example that can lead to focal neurological disease. This practice challenges you to think critically about the limitations of standard genetic tests and the biological reasons behind them . You will analyze why a test might fail and devise a superior strategy, gaining insight into the real-world problem-solving required to diagnose complex cases involving tissue-specific variants.",
            "id": "4504006",
            "problem": "A child presents with focal cortical dysplasia and intractable seizures. A post-zygotic variant in a cortical malformation gene within the mechanistic target of rapamycin (MTOR) pathway is suspected to underlie somatic mosaicism. From neurodevelopmental first principles, a mutation arising after fertilization can distribute unevenly across germ layers, yielding tissue-specific variant allele fractions. Next-Generation Sequencing (NGS) of blood leukocyte DNA is performed with read depth $N_{\\text{blood}} = 120$, an empirical per-base error rate $e_{\\text{blood}} = 0.005$ (that is, $0.5\\%$), a minimum alternate-read requirement $k_{\\min,\\text{blood}} = 8$, and a variant calling threshold for the observed variant allele fraction (VAF) $T_{\\text{blood}} = 0.05$ (that is, $5\\%$). The same patient has a skin biopsy to culture fibroblasts, and a targeted panel is planned with read depth $N_{\\text{fib}} = 300$, an error rate reduced by Unique Molecular Identifiers (UMIs) to $e_{\\text{fib}} = 0.002$, $k_{\\min,\\text{fib}} = 6$, and a VAF threshold $T_{\\text{fib}} = 0.02$ (that is, $2\\%$). Based on developmental lineage and clinical presentation, the true underlying mosaic fractions are estimated as $p_{\\text{brain}} = 0.20$ in the cortex, $p_{\\text{fib}} = 0.06$ in fibroblasts, and $p_{\\text{blood}} = 0.01$ in blood.\n\nUsing core definitions from genetics and probability (deoxyribonucleic acid replication, somatic mosaicism, and random sampling of alleles by sequencing reads), explain why the blood assay is at high risk for a false negative while the fibroblast assay is likely to detect the variant. In your explanation, derive whether the blood assay can realistically meet both its minimum alternate-read requirement and its VAF threshold, and contrast this with fibroblasts, taking into account the stated error rates and depths. Then, select the most appropriate testing strategy to mitigate false negatives for suspected somatic mosaicism in cortical malformation genes in clinical neurogenetic counseling.\n\nWhich option most appropriately mitigates the false-negative risk, given the scenario and principles?\n\nA. Repeat standard exome sequencing on blood at the same depth $N_{\\text{blood}} = 120$ while keeping $T_{\\text{blood}} = 0.05$ and $k_{\\min,\\text{blood}} = 8$ unchanged.\n\nB. Perform multi-tissue, ultra-deep targeted sequencing (for example, $\\ge 1000\\times$) using Unique Molecular Identifiers (UMIs) on fibroblasts and an ectoderm-derived tissue (for example, buccal epithelium), lower the reporting threshold to $T = 0.01$ with a calibrated minimum alternate-read requirement, confirm candidate variants with Digital Droplet Polymerase Chain Reaction (ddPCR), and include resected brain tissue if clinically available.\n\nC. Rely on parental trio sequencing to identify de novo variants in blood, keeping $T_{\\text{blood}} = 0.05$ and $k_{\\min,\\text{blood}} = 8$; if parents are negative, infer the child’s mosaicism.\n\nD. Switch to Sanger sequencing of saliva at standard coverage without UMIs, setting $T = 0.10$ (that is, $10\\%$) to avoid false positives from sequencing error.",
            "solution": "The problem statement is evaluated for validity prior to attempting a solution.\n\n### Step 1: Extract Givens\n- **Clinical Context:** A child with focal cortical dysplasia and intractable seizures.\n- **Hypothesis:** Somatic mosaicism due to a post-zygotic variant in a gene of the mechanistic target of rapamycin (MTOR) pathway.\n- **Biological Principle:** Post-zygotic mutations can lead to tissue-specific variant allele fractions (VAFs).\n- **Estimated True VAFs ($p$):**\n  - Brain cortex: $p_{\\text{brain}} = 0.20$\n  - Fibroblasts: $p_{\\text{fib}} = 0.06$\n  - Blood leukocytes: $p_{\\text{blood}} = 0.01$\n- **Blood NGS Assay Parameters:**\n  - Read depth: $N_{\\text{blood}} = 120$\n  - Per-base error rate: $e_{\\text{blood}} = 0.005$\n  - Minimum alternate-read requirement: $k_{\\min,\\text{blood}} = 8$\n  - VAF calling threshold: $T_{\\text{blood}} = 0.05$\n- **Fibroblast NGS Assay Parameters:**\n  - Read depth: $N_{\\text{fib}} = 300$\n  - Per-base error rate (with UMIs): $e_{\\text{fib}} = 0.002$\n  - Minimum alternate-read requirement: $k_{\\min,\\text{fib}} = 6$\n  - VAF calling threshold: $T_{\\text{fib}} = 0.02$\n- **Task:** Explain the differential risk of false negatives for the two assays and select the most appropriate testing strategy to mitigate this risk.\n\n### Step 2: Validate Using Extracted Givens\nThe problem statement is scientifically grounded, well-posed, and objective.\n- **Scientific Grounding:** The scenario is a classic and realistic representation of a clinical challenge in neurogenetics. Somatic mosaicism in MTOR pathway genes is a known cause of focal cortical dysplasia. The use of Next-Generation Sequencing (NGS), the concepts of read depth ($N$), variant allele fraction (VAF), sequencing error ($e$), minimum alternate reads ($k_{\\min}$), Unique Molecular Identifiers (UMIs), and tissue-specific mosaicism are all standard and correctly applied principles in modern genetics. The numerical values provided for VAFs, read depths, and error rates are plausible for clinical assays.\n- **Well-Posedness:** The problem is well-posed. It provides all necessary quantitative data to model the detection probability for each assay. The question is specific and answerable through logical and statistical reasoning based on the provided parameters. A unique, stable, and meaningful solution can be derived.\n- **Objectivity:** The problem is stated in precise, unbiased technical language, free of subjective claims.\n\n### Step 3: Verdict and Action\nThe problem statement is **valid**. Proceeding to solution.\n\n### Derivation and Explanation\n\nThe core of this problem lies in understanding that NGS is a random sampling process. For a given genomic locus with a true variant allele fraction $p$ in the tissue sample, the number of sequencing reads that report the variant allele, $k$, can be modeled by a binomial distribution. The detection of a variant requires that the observed data meet pre-specified criteria, designed to distinguish true biological signal from technical noise (sequencing errors).\n\nLet us model the number of observed alternate reads, $k_{\\text{obs}}$. This count is a combination of true variant reads ($k_{\\text{signal}}$) and reads that appear to be variants due to sequencing error ($k_{\\text{error}}$).\n- The number of true variant reads follows a binomial distribution, $k_{\\text{signal}} \\sim B(N, p)$. The expected number is $E[k_{\\text{signal}}] = Np$.\n- The number of error reads can be approximated by $k_{\\text{error}} \\sim B(N, e)$, where $e$ is the per-base error rate. The expected number is $E[k_{\\text{error}}] = Ne$.\n- The total expected number of observed alternate reads is $E[k_{\\text{obs}}] \\approx Np + Ne = N(p+e)$.\n- A detection is made if two conditions are met:\n  1. The number of observed alternate reads is at least the minimum required: $k_{\\text{obs}} \\ge k_{\\min}$.\n  2. The observed VAF is at least the threshold: $\\text{VAF}_{\\text{obs}} = k_{\\text{obs}}/N \\ge T$. This is equivalent to $k_{\\text{obs}} \\ge NT$.\n- A false negative occurs if the variant is truly present ($p > 0$) but either of these conditions is not met.\n\n**Analysis of the Blood Assay:**\n- Given parameters: $p_{\\text{blood}} = 0.01$, $N_{\\text{blood}} = 120$, $e_{\\text{blood}} = 0.005$, $k_{\\min,\\text{blood}} = 8$, $T_{\\text{blood}} = 0.05$.\n- The expected number of true variant reads is $E[k_{\\text{signal}}] = N_{\\text{blood}} \\times p_{\\text{blood}} = 120 \\times 0.01 = 1.2$.\n- The expected number of error reads is $E[k_{\\text{error}}] = N_{\\text{blood}} \\times e_{\\text{blood}} = 120 \\times 0.005 = 0.6$.\n- The total expected number of alternate reads is $E[k_{\\text{obs}}] \\approx 1.2 + 0.6 = 1.8$.\n- Now, let's check the detection criteria:\n  1. Minimum alternate reads: $k_{\\min,\\text{blood}} = 8$. The expected count of $1.8$ is far below this requirement. The probability of observing $8$ or more reads, when the expected number is only $1.8$, is exceedingly low. The process is governed by a binomial distribution $B(n=120, p' \\approx p_{\\text{blood}}+e_{\\text{blood}}=0.015)$. Observing a value so far in the tail of the distribution is a stochastic improbability.\n  2. VAF threshold: $T_{\\text{blood}} = 0.05$. This requires $k_{\\text{obs}} \\ge N_{\\text{blood}} \\times T_{\\text{blood}} = 120 \\times 0.05 = 6$ reads.\n- The stricter of the two requirements is $k_{\\min,\\text{blood}} = 8$. Since the expected number of alternate reads is only $1.8$, the assay is almost certain to fail to meet the $k_{\\text{obs}} \\ge 8$ condition, leading to a false negative. The true signal is too weak for the given assay parameters.\n\n**Analysis of the Fibroblast Assay:**\n- Given parameters: $p_{\\text{fib}} = 0.06$, $N_{\\text{fib}} = 300$, $e_{\\text{fib}} = 0.002$, $k_{\\min,\\text{fib}} = 6$, $T_{\\text{fib}} = 0.02$.\n- The expected number of true variant reads is $E[k_{\\text{signal}}] = N_{\\text{fib}} \\times p_{\\text{fib}} = 300 \\times 0.06 = 18$.\n- The expected number of error reads is $E[k_{\\text{error}}] = N_{\\text{fib}} \\times e_{\\text{fib}} = 300 \\times 0.002 = 0.6$.\n- The total expected number of alternate reads is $E[k_{\\text{obs}}] \\approx 18 + 0.6 = 18.6$.\n- Now, let's check the detection criteria:\n  1. Minimum alternate reads: $k_{\\min,\\text{fib}} = 6$. The expected count of $18.6$ is substantially higher than this requirement.\n  2. VAF threshold: $T_{\\text{fib}} = 0.02$. This requires $k_{\\text{obs}} \\ge N_{\\text{fib}} \\times T_{\\text{fib}} = 300 \\times 0.02 = 6$ reads.\n- Both requirements simplify to needing at least $6$ alternate reads. Given that the expected number of alternate reads is $18.6$, the random sampling process is highly likely to yield an observation $k_{\\text{obs}} \\ge 6$. The probability of this is very high, making a false negative unlikely. The higher VAF in fibroblasts ($p_{\\text{fib}} = 0.06$), the greater sequencing depth ($N_{\\text{fib}} = 300$), and the lower error rate ($e_{\\text{fib}} = 0.002$) all contribute to the high likelihood of detection.\n\nIn summary, the blood assay fails because the signal ($p_{\\text{blood}} = 0.01$) is too low relative to the assay's sensitivity limits, which are defined by its depth ($N_{\\text{blood}}$) and calling thresholds ($k_{\\min,\\text{blood}}, T_{\\text{blood}}$). The fibroblast assay succeeds because it uses a more appropriate tissue with a higher variant fraction, combined with a more sensitive assay design (deeper coverage and lower error rate).\n\n### Evaluation of Options\n\n**A. Repeat standard exome sequencing on blood at the same depth $N_{\\text{blood}} = 120$ while keeping $T_{\\text{blood}} = 0.05$ and $k_{\\min,\\text{blood}} = 8$ unchanged.**\nThis option proposes repeating an experiment that has already been demonstrated to be fundamentally inadequate for detecting the variant. Repeating the same flawed protocol will not change the outcome, aside from random chance providing a different but still likely negative result. It does not address the core issues of low VAF in blood and insufficient sequencing depth.\nVerdict: **Incorrect**.\n\n**B. Perform multi-tissue, ultra-deep targeted sequencing (for example, $\\ge 1000\\times$) using Unique Molecular Identifiers (UMIs) on fibroblasts and an ectoderm-derived tissue (for example, buccal epithelium), lower the reporting threshold to $T = 0.01$ with a calibrated minimum alternate-read requirement, confirm candidate variants with Digital Droplet Polymerase Chain Reaction (ddPCR), and include resected brain tissue if clinically available.**\nThis option systematically addresses all the weaknesses of the initial approach.\n- **Multi-tissue testing:** Acknowledges that blood is often a poor sample for somatic mosaicism affecting the brain. It proposes testing more relevant tissues: fibroblasts (as shown to be promising) and a tissue from the same germ layer as the brain (ectoderm), like buccal cells.\n- **Ultra-deep sequencing ($\\ge 1000\\times$):** Drastically increases the read depth ($N$), which provides the statistical power to confidently detect low-VAF variants. For $p=0.01$, $N=1000$ would yield an expected $10$ true variant reads.\n- **UMIs:** Reduces the sequencing error rate, improving the signal-to-noise ratio, which is critical for low-VAF calling.\n- **Lowered thresholds:** Adjusts the VAF threshold ($T=0.01$) to a level appropriate for the expected signal, with a $k_{\\min}$ that would be statistically determined to maintain specificity at the new read depth.\n- **Orthogonal confirmation (ddPCR):** Uses a highly sensitive and quantitative method to confirm findings, which is the standard of care.\n- **Brain tissue:** Prioritizes testing the affected tissue, where the VAF is highest ($p_{\\text{brain}} = 0.20$), if it becomes available through surgery.\nThis comprehensive strategy is the current best practice for detecting low-level somatic mosaicism.\nVerdict: **Correct**.\n\n**C. Rely on parental trio sequencing to identify de novo variants in blood, keeping $T_{\\text{blood}} = 0.05$ and $k_{\\min,\\text{blood}} = 8$; if parents are negative, infer the child’s mosaicism.**\nThis strategy is flawed. Trio sequencing is used to determine if a variant found in a child is inherited or arose *de novo* (i.e., not present in parents). The fundamental problem here is not determining the origin of the variant, but *detecting it in the first place*. This option still relies on the original blood assay parameters, which we have proven are insufficient to detect a VAF of $p_{\\text{blood}} = 0.01$. If the variant is not called in the child's data due to a false negative, the trio analysis is useless for this variant.\nVerdict: **Incorrect**.\n\n**D. Switch to Sanger sequencing of saliva at standard coverage without UMIs, setting $T = 0.10$ (that is, $10\\%$) to avoid false positives from sequencing error.**\nThis is a demonstrably worse strategy. Sanger sequencing is an older technology with a limit of detection around $15-20\\%$ VAF. It is completely incapable of detecting the suspected VAFs of $p_{\\text{fib}} = 0.06$ or $p_{\\text{blood}} = 0.01$. Raising the VAF threshold to $T = 0.10$ ($10\\%$) further guarantees a false negative result. While saliva contains ectoderm-derived buccal cells, the sequencing technology proposed is inappropriate for detecting mosaicism.\nVerdict: **Incorrect**.",
            "answer": "$$\\boxed{B}$$"
        }
    ]
}